Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dEbzCfbwocewwnetPTMv

May 9, 2012
Sign upForwardArchive
News for the PBM Industry

  Legislative & Regulatory News 
  • Study: Too many plans in exchanges could overwhelm consumers
    Allowing any insurance plan that meets a minimum set of criteria to participate in state-run exchanges could overwhelm consumers shopping for health insurance, according to a study published in Health Affairs. "Early focus groups showed that consumers wanted four to six carrier options at 'low, medium and high' benefit levels," the study authors wrote. The Hill/Healthwatch blog (5/8) LinkedInFacebookTwitterEmail this Story
  Drug Industry Spotlight 
  • Teva reports continued strength in U.S. generics sales
    Sales of Teva's branded drugs such as Copaxone, for multiple sclerosis, are up while sales of generic drugs remained strong in the United States in the first quarter of 2012. Teva is the world's largest maker of generics. Reuters (5/9) LinkedInFacebookTwitterEmail this Story
  • Global pharma M&A value up 75% in 2011
    The world biotech and pharmaceutical industry saw 504 deals in 2011, down from 548 the previous year, according to a report from IMAP. The total worth of the transactions, however, climbed 75% to $90 billion, and 81 deals were recorded in the $100 million-to-$1 billion range, up from 31. PharmaTimes (U.K.) (5/8) LinkedInFacebookTwitterEmail this Story
  • Study: Many drug labels lack safety and dosing data for children
    Many drug labels don't contain information on proper dosage and safety for children, according to an FDA study of 560 medications for diseases ranging from allergies to high blood pressure. "If you give a child a therapy and it doesn't work, it's hard to tell if your dose wasn't ideal or it's just because the drug didn't work," said Dr. Eric Lavonas, from the Rocky Mountain Poison and Drug Center in Denver. "Likewise, if a child has a side effect, it's hard to tell if that's a side effect of the drug or if the child wouldn't have had that side effect if the right dose was given." The findings were published in the Journal of the American Medical Association. Reuters (5/8) LinkedInFacebookTwitterEmail this Story
  SmartQuote 
Never grow a wishbone ... where your backbone ought to be."
--Clementine Paddleford,
American food writer


LinkedInFacebookTwitter

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

 
Contact PCMA
Charles Cote
Assistant Vice President, Strategic Communications
(202) 207-3610

Twitter  Follow PCMA on Twitter
 
About PCMA
PCMA is the national association representing America's pharmacy benefit managers (PBMs), which administer prescription drug plans for more than 210 million Americans with health coverage provided through Fortune 500 employers, health insurance plans, labor unions, and Medicare Part D. PCMA is dedicated to enhancing the proven tools and techniques pioneered by PBMs that generate savings and access for consumers and payors.

 
 Recent PCMA SmartBrief Issues:   Lead Editor:  Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information